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Background: Botulinum toxin A is a commonly used biological medication in the field of facial plastic surgery.
Currently, there are three distinct formulations of botulinum toxin A, each with their purported benefits and
advantages. However, there is considerable confusion as to the relative efficacy and side-effects associated with
each formulation. Therefore, the purpose of this paper is to systematically assess published studies and perform a
meta-analysis to determine if there is a significant advantage of any of the individual formulations.
Methods/design: A systematic literature search was performed for all relevant English language randomized
controlled trials using Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, World
Health Organization (WHO) International Clinical Trials Registry Platform, European Union (EU) Clinical Trials Register,
Cochrane Library databases of clinical trials, and ClinicalTrials.gov. Inclusion criteria included any randomized
controlled trial (RCT) that assessed the use of botulinum toxin for cosmetic purposes. The included articles were
also analyzed for bias using the Cochrane Collaboration’s tool for assessing the risk of bias in RCTs.
Discussion: The results of this review will provide clinicians with an unbiased, high level of evidence of the
comparative efficacy of individual preparations of botulinum toxin A.
Trial registration: PROSPERO: CRD4201200337
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Botulinum toxin type A is a commonly used biological
medication for a variety of medical and cosmetic indica-
tions. Currently, there are three commonly used formula-
tions of botulinum toxin A: onabotulinum toxin A (Botox
or Vistabel (Allergen, Irvine, CA, USA), incobotulinum
toxin A (Xeomin or Bocouture (Merz Pharmaceuticals,
Frankfurt, Germany), and abobotulinum toxin A (Dysport
(Medicis, Scottsdale, AZ, USA) or Azzalure (Ipsen, Paris,
France). Each formulation is purported to have unique
benefits; however, it is unclear if these differences are clin-
ically significant. Producers of each formulation often
highlight a number of factors distinguishing their product* Correspondence: DrJames.Bonaparte@gmail.com
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distribution, and reproduction in any mediumfrom their competitors. These features typically include:
dose potency and/or equivalency [1], the onset of action
[2], duration of action [3], local diffusion of the toxin [4,5],
side-effect profile [6], and differences in immunogenicity.
Manufacturers of botulinum toxin typically produce
their product as a 150 to 900 kDa protein. This protein in-
cludes both the primary active component (the 150 kDa
polypeptide chain) [7] as well as complexing proteins. The
150 kDa chain has low activity; however, once cleaved into
a 50 kDa (light chain) and a 100 kDa (heavy chain) the
toxin has the ability to exert its effect [7].
There is evidence to suggest that these complexing
proteins are primarily responsible for protecting the
toxin as it passes through mammalian gastrointestinal
tracts [8,9]. However, it has also been suggested that
these proteins are responsible for the development of
anti-toxin antibodies [10] which can result in the medi-
cation being ineffective. This is controversial since theretral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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these accessory proteins may be required for adequate
functioning of the active protein. For example, one of
these proteins has been shown to disrupt epithelial
integrity allowing the active protein entry into the
cell [11].
One of the primary differences between botulinum
toxin formulations is the presence or absence of these
complexing proteins [1]. The manufacturers of incobo-
tulinum toxin A use this feature in marketing to profes-
sionals, particularly with respect to the proposed low
potential for antigenicity [12]. From a marketing perspec-
tive, it is understandable that manufacturers highlight this
feature to distinguish it from other formulations. Clinic-
ally, however, it is unclear whether there is a significant ef-
fect of these molecular differences in terms of both
antigenicity and efficacy.
With respect to dose equivalency, previous data sug-
gest that abobotulinum toxin A and onabotulinum toxin
have non-parallel dose–response curves, and thus differ
in their relative potencies [1]. Studies often assess these
medications at varying dose ratios with abobotulinum
toxin requiring 2 to 3 times the relative dose in ‘units’
compared to the other formulations. Even though dosing
is described in terms of units, it is evident that the pre-
sumed clinical effect of 1 unit is not interchangeable be-
tween formulations [13]. In addition to this, even within
individual formulations, there is evidence to suggest that
the specific dose influences both efficacy as well as the
duration of effect, and therefore a comparison among
studies is often difficult if varying doses are used [14].
More controversial, is the relative potency between
onabotulinum and incobotulinum, since the dose in
units is often reported as equivalent. A meta-analysis of
the relative potency between these two medications was
recently published [15]. The author concluded that there
was no difference in relative potencies between the two
products using a standard unit dosing. However, this
study only assessed one outcome measure, response rate
at day 30, thus limiting its usefulness. It is unclear if this
method of dosing also results in similar outcomes with
respect to complication rates and long-term efficacy.
Furthermore, of the eight studies meeting the primary
inclusion criteria of the meta-analysis, only one study in-
cluded an assessment of incobotulinum toxin.
As a result of these controversies, a formal assessment
of all available evidence would assist clinicians and pro-
vide a summary of the evidence. Although previous
meta-analyses have been conducted, they have consider-
able limitations as well as narrow scopes of assessment.
One previous meta-analysis assessing the duration of ac-
tion of Botox did not include a formal systematic review,
but rather reviewed four self-identified ‘landmark stud-
ies’ [16]. Due to this method of study selection, there isa very high risk of bias. Gadhia and Walmsley (2009)
published a systematic review of botulinum toxin for fa-
cial aesthetics; however, this study only included trials
comparing each medication to a placebo and excluded
any active drug comparison [17]. Based on a pilot search
by our team, it appeared as though this study did not
identify a significant number of trials meeting their in-
clusion criteria. Furthermore, the authors did not under-
take a formal meta-analysis of the data. Flynn (2010)
conducted a review of the botulinum toxin preparations
as well as their individual duration of effect [18]. This
study identified a large number of peer-reviewed papers
incorporating both randomized and non-randomized tri-
als. This study identified great heterogeneity in terms of
the definition of duration of action and thus comparative
analysis was not attempted. Unfortunately, the inclusion
of a wide range of study designs made a non-biased in-
terpretation very difficult.
Due to the large number of non-randomized, non-
blinded, industry-sponsored trials, clinicians have great
difficulty determining if one specific medication carries
an advantage over others in terms of both efficacy and
safety. Furthermore, all previous reviews had significant
flaws, not limited to poor identification of articles, a lack
of a systematic review process as well as incomplete data
reporting. Given the large number of double-blind ran-
domized trials published assessing the cosmetic use of
botulinum toxin, a formal systematic review and meta-
analysis would assist physicians in making appropriate
decisions, particularly given the significant amount of
marketing by manufacturers. This review is also timely,
since incobotulinum has recently been approved by
Health Canada and the Food and Drug Administration
(FDA) in 2013.
Aims and objectives
The aim of this systematic review is to evaluate the com-
parative effectiveness and harms of three preparations of
botulinum toxin A for the treatment of facial wrinkling
in adult patients. When treating facial rhytides with
any one of the three botulinum toxin A formulations
(onabotulinum toxin A, incobotulinum toxin A and
abobotulinum toxin A) in adult patients, what are the
comparative treatment: 1) benefits in terms of time to
treatment response, patient and/or observer assessment
of rhytid reduction, and sustainability of treatment re-
sponse; and 2) harms in terms of procedural complica-
tions and adverse events?
Methods/design
This systematic review has been prospectively registered
(CRD4201200337) with the PROSPERO international pro-
spective register of systematic reviews [19]. The review
will comply with the standards and guidelines proposed by
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ventions [20]. Once completed, the reporting of our find-
ings will adhere to the standards of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [21].Eligibility criteria
Randomized controlled trials (RCTs) investigating the
cosmetic use of a particular formulation of botulinum
toxin A with no treatment, sham/placebo therapy, an-
other formulation of botulinum toxin A, or another ac-
tive treatment in adults with facial rhytides will be
included. We will only include studies published in the
English language. Studies which include additional cos-
metic treatments in addition to botulinum toxin A dur-
ing the study period (dermal fillers, skin care, or other
skin therapy) will be assessed if they meet the above in-
clusion criteria.Information sources and literature search
Literature search strategies will be developed in consult-
ation with an experienced librarian at the University of
Ottawa (ON, Canada). A second librarian at the University
of Toronto (ON, Canada) will perform an assessment of
the search strategy and provide peer feedback. A comput-
erized literature search will be performed independently
by two reviewers and records will be de-duplicated. Arti-
cles will be identified by searching Embase (via OVID),
Cumulative Index to Nursing and Allied Health Literature
(CINAHL), MEDLINE, World Health Organization
(WHO) International Clinical Trials Registry Platform,
European Union (EU) Clinical Trials Register, Cochrane
Library databases of clinical trials, and ClinicalTrials.gov
(National Institutes of Health, USA). Appendix A includes
the Embase and MEDLINE search strategies. Additionally,
references of the retained articles will be reviewed to iden-
tify additional relevant articles that were not found with
the initial search strategy. A search for other published
systematic and standard reviews will be conducted to as-
sess reference lists for missed articles. Company represen-
tatives from each of the three botulinum toxin
formulations will be contacted to request unpublished trial
data as well as to ensure all relevant trials have been
identified.
To search the WHO International Clinical Trials Regis-
try Platform, EU Clinical Trials Register, Cochrane Library
databases and ClinicalTrials.gov, four searches will be
conducted, each with one of the following keywords: botu-
linum toxin as well as each of the medication drug and
trade names. Only clinical trials listed as completed will be
included in the search. The search will be limited to arti-
cles published between the 1970 and 2013, since botu-
linum toxin A was not developed prior to this date.Study selection process
Three reviewers will independently review record titles
and abstracts to assess eligibility (JB, JQ, DE). Eligible ar-
ticles will be independently reviewed by the same three
reviewers in full-text form for formal inclusion in the
final review. All disagreements between reviewers will be
resolved during a consensus meeting. These reviewers
will also assess the possibility of duplicate publications.Data items and data collection process
Standardized forms for data extraction will be created
after pilot testing on a small subset of publications. All
data will be extracted by the lead investigator (JB) and
confirmed by two co-investigators (DE and JQ).
The following data will be extracted from all included
studies: 1) study characteristics: author list, primary
country of study, year of publication, specific type of
randomized trial, duration of follow-up, number of pa-
tients randomized and participating in trial, and number
and cause of drop-outs. The funding source and any
other conflicts of interest will be recorded; 2) patient
demographics: inclusion and exclusion criteria, age, gen-
der, ethnicity/race, severity/classification and location of
rhytides, comorbidity and co-medications, and time of
previous botulinum injections (if any); 3) intervention
and comparator characteristic: type of botulinum toxin
A, total dose (units) and volume injected, concentration
of medication, site(s) of injection and number of injec-
tions per treatment, number and frequency of treatment
schedules, periprocedural precautions, injection tech-
niques and gauge of needles used, provider training and
experience (for example, physician injector versus nurse,
injector patient volume per year and number of years
injecting botulinum toxin), and relevant details of any
other active comparator treatment; 4) outcomes: the
pre-specified outcomes of interest are categorized and
itemized in Table 1. Numerical outcomes data will be
extracted along with their definitions, scales (for ex-
ample facial wrinkle scale (FWS) [22] and glabellar line
severity scale (GLSS) [23]), cut-off thresholds used for
categorical data (for example, change in facial wrinkle
scale of 2 required for successful treatment), and
methods of assessment and monitoring.Risk of bias assessment
Using the Cochrane Collaboration’s tool for assessing risk
of bias, three reviewers (JB, DE, JQ) will assess for risk of
selection, performance, detection, attrition, reporting and
other biases for all included studies by outcomes of interest
[24]. A minimum of two reviews assessing the same risk
will be required to assign a particular risk to a study charac-
teristic. If each review scores a paper uniquely, this will be
resolved at a consensus meeting. Additionally, for harms
Table 1 A priori outcomes of botulinum toxin therapy
Outcomes of treatment effectiveness
Time to treatment response or onset of action (based upon patient
or expert/observer reported response assessment)
Duration of action or sustainability of response
Patient reported improvement at 30 days, and between 112 and
120 days, or nearest approximations
Expert/observer reported improvement at 30 days, and between 112
and 120 days, or nearest approximations
Changes in quality of life (assessed using validated instruments)
Detection of neutralizing antibodies
Short-term unintended effects of treatment or treatment delivery
(harms)




Use of botulinum anti-toxin
Headaches
Flu-like malaise
Longer-term unintended effects of treatment (harms)
Functional neurologic deficits or disfigurements (for example brow or
lid ptosis, blepharoptosis, ectropion or entropion)
Strabismus and diplopia
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collected or passively measured when required.
Data synthesis
Results will be reported descriptively first. Outcome data
may be available as dichotomous, continuous, count, or
time-to-event data. Relative risk for dichotomous out-
comes, mean difference, ratio of means, or standardized
mean differences for continuous, rate ratios of counts,
and hazard ratios of time-to-event data will be preferred
measures of analysis. Studies with zero events in one
arm will be meta-analyzed without continuity correction
with either the Peto method or the Mantel-Haenszel
method [25]. Studies with zero events in both arms will
be excluded from meta-analyses. When adequate head-
to-head trails are available, meta-analysis will follow rou-
tine methods for pooling across studies, provided there
are no major concerns about methodological and clinical
diversity between studies. The random effects approach
of DerSimonian and Laird will be employed for meta-
analysis [26].
Indirect comparisons will be undertaken in a network
meta-analysis (NMA) to investigate comparative effec-
tiveness across the three botulinum toxins when direct evi-
dence is deemed imprecise or absent for a given outcome.
NMA is an approach to evidence synthesis which allows
for the combination of direct and indirect comparativeevidence of three or more treatments in a unified analysis.
The applicable scenario is when treatments A and B are
compared with each other when no (or few) trials of A ver-
sus B exist (that is no direct head-to-head evidence), but
substantial evidence exists for trials of A versus C and B
versus C exist (indirect evidence) [27-29].
It is possible that studies may have assigned interven-
tions in trials of multiple body parts in the following two
ways: 1) patients were randomized to one or another
intervention, but each intervention was applied to mul-
tiple body sites and data were analyzed by body sites
(outcomes data from such studies would be impacted by
a clustering effect to be accounted for in our meta-
analysis); and 2) each patient’s multiple body sites were
randomized (the split-body design) to two different in-
terventions and data were analyzed as if each site were a
patient (outcomes data from such studies would be im-
pacted by a crossover effect to be accounted for in our
meta-analysis).
For these studies, appropriate analyses would need to
factor in either the intra-class or intra-cluster correlation
coefficient, or the within-patient differences and paired
analysis, respectively, in addition to the between patient
variability. If this is not possible, the resulting unit of
analysis error may impact the precision of study sum-
mary estimates (more precise or less precise, respect-
ively), thereby leading to inappropriate weighting in the
meta-analysis [20].
Statistical heterogeneity between studies will be quan-
tified with I-squared statistics and the P value from the
chi-squared test (a P value of ≤0.10 instead of 0.05 will
be used to determine statistical significance). Sparse data
will not be meta-analyzed but described narratively.
Meta-regression with multiple study level covariates
will be attempted when there are at least six moderate
to large size studies for a continuous covariate and at
least four studies for each level of a categorical covariate.
Otherwise, clinical and methodological diversity in stud-
ies will be explored in subgroup analysis for the follow-
ing study level covariates, data permitting [25]: 1)
methodological covariates: study risk of bias and study
design (trials using a split-body design versus those with-
out or a cluster design); and 2) clinical covariates: age,
sex, region of study conduct (developed versus develop-
ing countries), and prior use of toxins and procedural
variability (for example expertise, precautions, needle
used, dose of toxin, injection technique).
When quantitative synthesis is deemed inappropriate,
a qualitative synthesis of data will be presented.
Grading the strength of evidence and assessment of
applicability
For a given outcome, reviewers’ confidence of the body of
evidence in support of a conclusion will be graded as per
Bonaparte et al. Systematic Reviews 2013, 2:40 Page 5 of 7
http://www.systematicreviewsjournal.com/content/2/1/40previously published guidance [30]. Mandatory domains
that will be assessed include risk of bias, consistency, dir-
ectness and precision. Our pre-specified gradable out-
comes are outcomes that are most likely to influence
decision-making. They include: 1) patient reported out-
comes (onset, efficacy at day 30 and duration of effect);
2) expert observer reported outcomes (onset, efficacy at
day 30 and duration of effect); 3) local neurological defects
or disfigurement; 4) headache; and 5) incidence of Botox
non-responders post-therapy. For the body of evidence,
we will summarize the population, intervention, compara-
tor, setting and study duration data that may be used to
assess external validity of evidence by various stakeholders
and decision makers.
Discussion
From a historical perspective, onabotulinum toxin A
(Botox) was initially approved by the FDA for the treat-
ment of strabismus and blepharospasm in 1989. In 2001,
onabotulinum toxin A was approved for moderate to se-
vere glabellar rhytides by Health Canada, followed by
the FDA and EU in 2002. France, Spain and the UK
soon followed in 2003, 2004 and 2006, respectively. Abo-
botulinum toxin A (Dysport) was not approved by the
FDA for glabellar rhytides until 2009 and is still not ap-
proved by Health Canada for cosmetic indications. In
2012, a new botulinum formulation, incobotulinum
toxin A (Xeomin), was approved by Health Canada for
glabellar wrinkling. This product has been available in
Europe and is expected to be approved for glabellar
wrinkling in the USA by 2013. Given the anticipated ap-
proval by the FDA of a new medication, we feel this re-
view will provide clinicians with the opportunity to read
a non-biased, critical appraisal of the current status of
the literature.
Although we are confident this review will achieve our
objective, it is important to note that there are antici-
pated limitations and challenges. One anticipated diffi-
culty relates to reporting and grading of outcomes,
particularly efficacy outcomes. Typically, both clinicians
and patients rate the extent of their wrinkling using vali-
dated scales. Commonly, the FWS is the primary out-
come measure for clinician assessments, while the
subject global assessment (SGA) scale is used for patient
self-assessment [31]. The FWS consists of a 4-point or-
dinal scale ranging from no wrinkling to severe wrink-
ling. This scale is accompanied by a photo guide to
assist in appropriate grading. The SGA is a percentage
measure used to assess a change in appearance with a
range from −100% to +100% improvement. Unfortuna-
tely, both these scales have been demonstrated to have
low to moderate inter-rater reliability [31]. An additional
scale, the GLSS [32], has demonstrated reasonable reli-
ability measures. Similar to the FWS, this is a 4-pointscale with photo guide. Interobserver reliability was
noted to be 0.62, while intraobserver reliability was be-
tween 0.57 and 0.91. Furthermore, it is likely that not all
studies will utilize one or both of these scales, thus com-
plicating direct comparisons.
In addition to the actual grading method, there is
likely to be variability across studies in terms of the def-
inition of a ‘positive effect’ of treatment. The majority of
studies reviewed in a pilot search defined a reduction in
the FWS of 2 points as a positive effect; however, a num-
ber of studies utilized a reduction of 1 point as the def-
inition of effect. Furthermore, some studies only
included patients who started the trial with a baseline
score of 2 or 3, while others included all baseline scores.
To complicate issues further, facial wrinkling of patients
can be assessed at rest or at maximum frown/motion,
which can accentuate different areas of the face.
An additional potential difficulty will be an assessment
of duration of action. Studies often utilize a variety of
methods to determine and define ‘duration’. Similar to
efficacy, rating scales along with a definition of response
are used and followed over time until a percentage of
patients no longer meet the definition of a response at a
predetermined time point. However, there is no guide-
line as to what percentage truly represents duration. Fur-
thermore, a major confounding variable in this regard is
related to the notion that patients who have repeated
treatments with botulinum toxin may have longer dura-
tions than naive patients, since there is a potential for
muscle atrophy. Both factors create considerable diffi-
culty when determining overall duration of action.
A more controversial topic is the development of anti-
botulinum toxin antibodies. This study will attempt to
identify cases of antibody development; however, we an-
ticipate a number of difficulties. The evidence currently
available for cosmetic botulinum toxin use suggests that
although the incidence is low, there is an increased risk
with repeated injections, particularly if high doses are
utilized [33]. We anticipate that the majority of studies
will have an inclusion criteria limiting the prior toxin
use, thus there may be a considerable selection bias in
terms of assessing immunogenicity. Nevertheless, we will
collect this data, since it is both clinically important and
highlighted as a potential distinguishing feature between
toxin formulations in company marketing. Unfortu-
nately, it is unlikely that these studies will perform for-
mal serum antibody testing, thus reporting of antibody
development is likely to be subjective and based on pas-
sive reporting. Ideally, studies should perform formal
serum antibody testing to adequately identify potential
non-responders. Interestingly, it is believed that if anti-
bodies develop, switching to an alternate formulation
may allow for continued treatment without the antibody
targeting that specific formulation. The results of two
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ching formulations to an additional formulation of botu-
linum toxin A did not result in a positive result. In two
cases, patients were switched to onabotulinum, while in
another two cases patients were switched to incobo-
tulinum, both continuing to demonstrate a lack of effi-
cacy due to antibodies [34]. We hope that this review
will help to provide further evidence as well as guidance
in this regard.
Even considering the potential difficulties, this review
will provide clinicians and surgeons with the most up-
to-date, unbiased evidence available, and will benefit pa-
tients and practitioners in the expanding field of facial
cosmetic medicine.
Appendix A
For Embase, the following strategy was used:
1) cosmetic/or dermatological agent/(20,732)
2) rhytidoplasty/or skin surgery/(7,339)
3) esthetic surgery/(10,534)
4) face surgery/or minor surgery/or plastic surgery/or
skin surgery/(68,088)
5) “rhytid”.ti,ab. (51)
6) (cosmetic adj3 (procedure or injection or drug)).ti,
ab. (955)
7) “frown lines”.ti,ab. (113)
8) “crow’s feet”.ti,ab. (210)















23) 11 and 22 (968)
24) from 23 keep 1–968 (968)
For MEDLINE, the following strategy was used:
1) cosmetics/(5,232)
2) rhytidoplasty/(2,479)
3) cosmetic techniques/or rhytidoplasty/(4,807)
4) otolaryngology/or surgery, plastic/(31,779)
5) “rhytid*”.ab,ti. (1,437)
6) (cosmetic adj3 (procedure or injection or drug)).ab,
ti. (737)
7) “frown lines”.ab,ti. (95)
8) “crow’s feet”.ab,ti. (157)9) wrinkle$.ab,ti. (3,052)
10) (muscle* adj3 (frontalis or procerus or orbicularis)).
ab,ti. (1,703)
11) (muscle$ adj3 “corrugator supercilii”).ab,ti. (87)
12) or/1-11 (46,436)










23) or/13 to 22 (11,294)
24) 12 and 23 (786)
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